ATP7B and Wilson disease: In addition, it is tempting to speculate how in the future structure–activity relation studies and drug design approaches might eventually lead to the identification of novel peptidomimetic molecules to be used as “functional agonist” of the ATP7B-H1069Q mutant for therapeutic purposes in Wilson disease.